Bio-Rad Labs (NYSE: BIO) reported Q3 EPS of $0.91, $0.24 worse than the analyst estimate of $1.15. Revenue for the quarter came in at $545.1 million versus the consensus estimate of $538.68 million.

2018 Financial Outlook

For the full year 2018, the company is reiterating the previous currency-neutral growth revenue outlook of 4.0 to 4.5 percent. Given the lower than anticipated gross margin result for the first nine months of the year, the company now anticipates a full year currency-neutral operating margin of 8.0 to 9.0 percent, or an estimated 9.5 to 10.5 percent on a non-GAAP basis, which compares to the previous non-GAAP estimate of 11.0 to 11.5 percent. Management will discuss this outlook in greater detail on the third quarter 2018 financial results conference call.

“As we head into the end of the year, we anticipate 2018 will be another year of growth in many of our key product areas as well as broad contribution from most of our major geographies,” Mr. Schwartz said. “While the operating performance for the year is not as strong as we would have liked, we still project that 2018 will reflect substantial improvement in operating profit over 2017.”

For earnings history and earnings-related data on Bio-Rad Labs (BIO) click here.